Overview

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome

Status:
Terminated

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

This study will investigate the effects of sertraline in people with low-risk myelodysplastic syndrome (MDS). It is hoped that sertraline will decrease disease progression and reduce the need for blood transfusions.

Phase:

Phase 1

Details

Lead Sponsor:

Gustavo Rivero

Collaborator:

Baylor College of Medicine

Treatments:

Sertraline